We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal

By HospiMedica International staff writers
Posted on 06 Mar 2026

Successful cancer surgery relies on a surgeon’s ability to remove tumors while preserving as much healthy tissue as possible. More...

To assist with this, surgeons often use fluorescent dyes that cause cancer cells to glow under special imaging systems. However, current dyes are not perfectly selective and can sometimes illuminate healthy tissue, making it difficult to distinguish tumors clearly during surgery. Researchers have now developed a new fluorescence system designed to highlight tumors with far greater precision.

Researchers at the University of Tokyo (Tokyo, Japan) have created what they describe as a bioorthogonal fluorescence probe paired with a specially engineered reporter enzyme that activates the probe only at targeted tumor sites. Unlike traditional probes that may be triggered by natural enzymes found throughout the body, this new probe remains inactive unless it encounters its matching engineered enzyme. This design significantly reduces unwanted background fluorescence.

To test the system, researchers delivered the engineered enzyme to tumor sites in mice with peritoneal cancer. Once the enzyme accumulated in the tumor tissue, the fluorescent probe was administered. The probe activated only when it encountered the engineered enzyme, causing the tumors to light up clearly. The study, published in American Chemical Society, shows that the approach allowed scientists to detect millimeter-sized tumor lesions with very low background fluorescence. The high contrast made tumors easier to distinguish from surrounding healthy tissue, potentially improving surgical precision.

Researchers believe this technology could eventually help surgeons identify and remove tumors more accurately during cancer surgery. The enzyme–probe system may also be adaptable to other cancer types by modifying the tumor-targeting component, such as using antibodies that recognize specific tumor markers. In addition to imaging, the approach could potentially be used for targeted drug delivery, where therapeutic agents are activated only at tumor sites. However, the current results are based on mouse studies, and further research is required before the technology can be tested in humans.

“Older probes often light up healthy tissue by mistake, creating background noise, but our highly selective, or bioorthogonal, dye probe is designed to stay completely off unless it meets its matching engineered enzyme,” said Associate Professor Ryosuke Kojima. “In the near term, this system could become a powerful research tool, and in the longer term, it may help surgeons remove tumors more completely by clearly highlighting cancer cells.’

Related Links:
University of Tokyo


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Rapid Sepsis Test
SeptiCyte RAPID
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: Adobe Stock

Noninvasive Brain-Computer Interface Enables Responses in Some Unresponsive ICU Patients

Cognitive motor dissociation occurs when patients retain signs of consciousness but cannot move or speak to communicate. In the ICU, this hidden consciousness can be difficult to distinguish from coma... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.